Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib or sorafenib plus gemcitabine and cisplatin for metastatic collecting duct carcinoma
chictr-onc-11001681Phase 4Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib, sorafenib, gemcitabine and cisplatin in collecting duct carcinoma (CDC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival. Started Jun 2008; status: completed.
02
Drugs
sunitinibsorafenibgemcitabinecisplatin
03
Conditions
collecting duct carcinoma (CDC)
Beyond the preview
Go deeper on chictr-onc-11001681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on chictr-onc-11001681.